Perspective Therapeutics, Inc.
AMEX:CATXMedical - Devices
+$0.02 today
- Market cap
- $94.20M
- Beta
- 1.73
- P/E (TTM)
- -0.0
- EPS (TTM)
- -$107.27
Volume 2.69M
Average 1.44M
CATX EBITDA
Earnings before interest, taxes, depreciation, and amortization; a proxy for operating profit before non-cash and financing charges.
Perspective Therapeutics, Inc.AMEX: CATX
EBITDA · Q1 FY2026 · quarter ended Mar 2026
EBITDA remains negative
Q1 FY2026 EBITDA was -$27.16M, compared with -$17.32M a year earlier. Trailing-twelve-month EBITDA was -$110.64M.
Context
- EBITDA amounted to 11402.8% of revenue in FY2025, up 10683.5 pp from a year earlier.
- EBITDA increased in 1 of the last 3 fiscal years.
- FY2025 was the lowest annual figure in the 4 fiscal years shown.
What to watch
Whether EBITDA reaches the consensus estimate from 9 analysts of -$69.79M (+30.8%) for the fiscal year ending Dec 2026, a step up from the -1063.8% reported in FY2025.
Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.
- Latest quarterMar 2026
- -$27.16M+27.0% QoQ
- Last fiscal yearDec 2025
- -$100.8M-1063.8% YoY
- LTMMar 2026
- -$110.64M-31.7% YoY
| Horizon | Past | Forecast | Difference |
|---|---|---|---|
| Quarter | -56.8% | -37.6% | +19.2 pp |
| 1 year | -1063.8% | +30.8% | +1094.5 pp |
| 3-year CAGR | — | — | — |
| 5-year CAGR | — | — | |
| 10-year CAGR | — | — |
Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.
EBITDA history
USD · from the income statement
- Latest · FY2025
- (100.8M) USD
- Year-over-year change
- -1063.8%
| Period | Period end | EBITDA | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | (100.8M) | -1063.8% |
| FY2024 | 2024-12-31 | 10.46M | +126.2% |
| FY2023 | 2023-12-31 | (39.96M) | -169.3% |
| FY2022 | 2022-12-31 | (14.84M) | -100.8% |
| FY2021 | 2022-06-30 | (7.39M) | — |
EBITDA vs competitors
How CATX compares with its peers on the latest reported figures
- CATX's LTM Mar 2026 EBITDA of -$110.64M is the 4th highest of the 5 companies compared; the peer median is -$14.48M.
- Its year-over-year change of -31.7% is the 3rd highest of 5, against a peer median of -48.8%.
- EBITDA amounts to 17902.8% of revenue for CATX, versus a peer median of 29.3%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $1.67M | +1154.1% | — | 1.8% | |
| LTM Mar 2026 | -$8.01M | -304.4% | — | 35.5% | |
| LTM Mar 2026 | -$20.95M | +5.5% | — | 46.7% | |
| LTM Mar 2026 | -$110.64M | -31.7% | — | 17902.8% | |
| LTM Mar 2026 | -$155.38M | -103.1% | — | 23.0% | |
| Peer median (excluding CATX) | -$14.48M | -48.8% | — | 29.3% | |
Competitors are the stored peer set for CATX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Jun 2022 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 10.8M | 7.1M | 1.43M | 1.45M | 884K |
| Cost of Revenue | 6.18M | 5.47M | 0 | 0 | 0 |
| Gross Profit | 4.62M | 1.63M | 1.43M | (852K) | (2.37M) |
| Gross Margin | 42.8% | 23.0% | 100.0% | -58.6% | -267.8% |
| Research & Development | 2.58M | 2.6M | 21.31M | 41.64M | 84.22M |
| Selling, General & Admin | 9.43M | 14.21M | 21.06M | 26.61M | 30.23M |
| Operating Expenses | 12.01M | 17.43M | 42.38M | 92.34M | 113.56M |
| Depreciation & Amortization | 248K | 344K | 981K | 2.31M | 3.25M |
| EBITDA | (7.39M) | (14.84M) | (39.96M) | 10.46M | (100.8M) |
| EBITDA Margin | -68.5% | -208.9% | -2786.6% | 719.3% | -11402.8% |
| Operating Income | (7.39M) | (15.18M) | (40.94M) | 10.46M | (113.56M) |
| Operating Margin | -68.5% | -213.7% | -2855.0% | 719.3% | -12846.6% |
| Interest Income | 119K | 1.12M | 934K | 10.52M | 8.11M |
| Interest Expense | 119K | 0 | 84K | (48K) | 376K |
| Other Income / Expenses | 119K | 512K | 835K | (91.84M) | 9.14M |
| Income Before Tax | (7.27M) | (14.67M) | (40.11M) | (81.38M) | (104.43M) |
| Pre-Tax Margin | -67.4% | -206.5% | -2796.8% | -5596.7% | -11813.1% |
| Income Tax Expense | (119K) | 0 | (2.65M) | (2.1M) | (793K) |
| Net Income | (7.15M) | (14.67M) | (46.51M) | (79.28M) | (103.12M) |
| Net Margin | -66.3% | -206.5% | -3243.2% | -5452.5% | -11665.3% |
| EPS (Basic) | (0.13) | (0.27) | (0.85) | (1.23) | (1.40) |
| EPS (Diluted) | (0.13) | (0.27) | (0.85) | (1.23) | (1.40) |
| Weighted Avg Shares | 54.91M | 54.91M | 54.91M | 64.43M | 73.81M |
| Weighted Avg Shares (Diluted) | 54.91M | 54.91M | 54.91M | 64.43M | 73.81M |
Perspective Therapeutics, Inc.
AMEX:CATX
Intrinsic Alpha fair value
Locked
Current Price
$0.78
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.